Akoya Biosciences (NASDAQ:AKYA – Get Free Report) had its price target lowered by stock analysts at Canaccord Genuity Group from $6.00 to $3.50 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 51.52% from the stock’s current price.
Several other equities analysts have also commented on the stock. Morgan Stanley lowered shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $4.00 to $3.00 in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lowered shares of Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 6th. Piper Sandler decreased their price objective on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $7.00 to $5.00 in a report on Friday. Finally, BTIG Research downgraded Akoya Biosciences from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.57.
Check Out Our Latest Analysis on AKYA
Akoya Biosciences Stock Performance
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Regal Investment Advisors LLC increased its stake in Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after acquiring an additional 7,340 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after buying an additional 9,429 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Akoya Biosciences by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 1,454,288 shares of the company’s stock worth $6,821,000 after acquiring an additional 46,131 shares in the last quarter. GSA Capital Partners LLP grew its position in Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after acquiring an additional 144,903 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC acquired a new stake in Akoya Biosciences during the 1st quarter valued at $2,724,000. 79.42% of the stock is currently owned by institutional investors and hedge funds.
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Featured Stories
- Five stocks we like better than Akoya Biosciences
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Top-Performing Non-Leveraged ETFs This Year
- What is the S&P/TSX Index?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.